Park JH, Han K, Hong JY, et al. - A decreased risk of pancreatic cancer was observed in relation to recovering from metabolic syndrome (MetS) vs persistent MetS, therefore, changes in MetS can modify the risk of pancreatic cancer.

• This is a nationwide cohort study of 8,203,492 adults without cancer; of these, 8,010 developed pancreatic cancer during follow-up (median, 5.1 years).

• Relative to the MetS-free group, the highest risk of pancreatic cancer (hazard ratio [HR] 1.30) was evident in the MetS-persistent group, followed by the MetS-developed group (HR 1.17) and the MetS-recovered group (HR 1.12) post-adjustment for potential confounders.

• The link between alterations in MetS status and pancreatic cancer risk did not differ by gender or obesity.